Synovus Financial’s Anika Therapeutics ANIK Stock Holding History

Synovus Financial’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-741	Closed	-$28K	–	731
2020 Q2	$28K	Hold	741	–	–	﹤0.01%	1023
2020 Q1	$21K	Hold	741	–	–	﹤0.01%	1347
2019 Q4	$38K	Hold	741	–	–	﹤0.01%	988
2019 Q3	$41K	Hold	741	–	–	﹤0.01%	950
2019 Q2	$30K	Hold	741	–	–	﹤0.01%	933
2019 Q1	$22K	Sell	741 -648	-47%	-$22.2K	﹤0.01%	991
2018 Q4	$47K	Sell	1,389 -271	-16%	-$9.78K	﹤0.01%	801
2018 Q3	$70K	Buy	1,660 +1,089	+191%	+$43K	﹤0.01%	766
2018 Q2	$19K	Hold	571	–	–	﹤0.01%	952
2018 Q1	$28K	Buy	+571	New	+$32.3K	﹤0.01%	860

Other funds holding ANIK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Baird Financial Group Milwaukee, Wisconsin $72.7B AUM 26.4% 1-Year Est. Return

Synovus Financial's ANIK Position: Q3 2020 in Review

Synovus Financial sold out of Anika Therapeutics (ANIK) in Q3 2020, closing a stake of 741 shares — an estimated $28K sold.

Synovus Financial first reported a position in ANIK in Q1 2018 and held it in 10 quarters. The position peaked at $70K in Q3 2018. 156 funds tracked by Wall St. Rank hold ANIK as of Q3 2020.

Synovus Financial reported no remaining Anika Therapeutics position as of Q3 2020 after selling out during the quarter.
Synovus Financial sold 741 Anika Therapeutics shares in Q3 2020, an estimated $28K.
Synovus Financial first reported a position in Anika Therapeutics in Q1 2018 and held it in 10 quarters.
Synovus Financial's Anika Therapeutics position peaked at $70K in Q3 2018.
156 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2020.

Based on Synovus Financial's 13F filing for Q3 2020, filed 9 Nov 2020.